178 related articles for article (PubMed ID: 38041093)
1. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
[TBL] [Abstract][Full Text] [Related]
2. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
[TBL] [Abstract][Full Text] [Related]
3. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
Ricciuti B; Elkrief A; Alessi J; Wang X; Li Y; Gupta H; Muldoon DM; Bertram AA; Pecci F; Lamberti G; Di Federico A; Barrichello A; Vaz VR; Gandhi M; Lee E; Shapiro GI; Park H; Nishino M; Lindsay J; Felt KD; Sharma B; Cherniack AD; Rodig S; Gomez DR; Shaverdian N; Rakaee M; Bandlamudi C; Ladanyi M; Janne PA; Schoenfeld AJ; Sholl LM; Awad MM; Cheng ML
Clin Cancer Res; 2023 Jul; 29(13):2540-2550. PubMed ID: 37097610
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
Hwang J; Shi X; Elliott A; Arnoff TE; McGrath J; Xiu J; Walker P; Bergom HE; Day A; Ahmed S; Tape S; Makovec A; Ali A; Shaker RM; Toye E; Passow R; Lozada JR; Wang J; Lou E; Mouw KW; Carneiro BA; Heath EI; McKay RR; Korn WM; Nabhan C; Ryan CJ; Antonarakis ES
Clin Cancer Res; 2023 Jul; 29(14):2702-2713. PubMed ID: 37126020
[TBL] [Abstract][Full Text] [Related]
8. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
Gu W; Zhuang W; Zhuang M; He M; Li Z
Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Weber AM; Drobnitzky N; Devery AM; Bokobza SM; Adams RA; Maughan TS; Ryan AJ
Oncotarget; 2016 Sep; 7(38):60807-60822. PubMed ID: 27602502
[TBL] [Abstract][Full Text] [Related]
10. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
11. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
[TBL] [Abstract][Full Text] [Related]
12. Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis.
Yamamoto K; Nihrane A; Aglipay J; Sironi J; Arkin S; Lipton JM; Ouchi T; Liu JM
Mol Med; 2008; 14(3-4):167-74. PubMed ID: 18224251
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the Fanconi Anemia DNA Repair Pathway by Phosphorylation and Monoubiquitination.
Ishiai M
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828369
[TBL] [Abstract][Full Text] [Related]
14. Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability.
Kim HS; Choi SI; Min HL; Kim MA; Kim WH
PLoS One; 2013; 8(12):e82769. PubMed ID: 24324828
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
16. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function.
Collins NB; Wilson JB; Bush T; Thomashevski A; Roberts KJ; Jones NJ; Kupfer GM
Blood; 2009 Mar; 113(10):2181-90. PubMed ID: 19109555
[TBL] [Abstract][Full Text] [Related]
17. The Fanconi anemia ID2 complex: dueling saxes at the crossroads.
Boisvert RA; Howlett NG
Cell Cycle; 2014; 13(19):2999-3015. PubMed ID: 25486561
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
19.
Mou J; Hu T; Wang Z; Chen W; Wang Y; Zhang W
Aging (Albany NY); 2020 Apr; 12(8):7465-7479. PubMed ID: 32329754
[TBL] [Abstract][Full Text] [Related]
20. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
